Top-News

QRXPHARMA LTD ADR News

Keine aktuellen Kursdaten verfügbar
WKN: A0YFSE
ISIN: US74733C1027
Typ: Aktie

QRXPHARMA LTD ADR News

11.07.14 - PR Newswire
QRxPharma Provides Feedback On End-of-Review Meeting With The FDA On Moxduo®
QRxPharma Provides Feedback On End-​of-Review Meeting With The FDA On Moxduo® PR Newswire
09.07.14 - PR Newswire
QRxPharma Announces Board Resignations
QRxPharma Announces Board Resignations PR Newswire
27.05.14 - PR Newswire
QRxPharma Receives Complete Response Letter From FDA Regarding Moxduo® NDA
QRxPharma Receives Complete Response Letter From FDA Regarding Moxduo® NDA PR Newswire
23.04.14 - PR Newswire
QRxPharma Issues Statement On Moxduo® Advisory Committee Meeting
QRxPharma Issues Statement On Moxduo® Advisory Committee Meeting PR Newswire
24.03.14 - PR Newswire
FDA Sets 22 April 2014 For Moxduo® Advisory Committee Meeting
FDA Sets 22 April 2014 For Moxduo® Advisory Committee Meeting Committee to Review Respiratory Safety Data Comparing Moxduo with Components PR Newswire
13.12.13 - PR Newswire
QRxPharma Completes A$11.6 Million Capital Raising
QRxPharma Completes A$11.6 Million Capital Raising Funding to provide working capital through CY2014, including anticipated launch of MOXDUO® PR Newswire
26.11.13 - PR Newswire
QRxPharma Refiles MOXDUO® New Drug Application with the FDA
QRxPharma Refiles MOXDUO® New Drug Application with the FDA Provides Additional Documentation Requested to Position Product for Approval in Q2 2014 PR Newswire
13.11.13 - PR Newswire
QRxPharma Announces Successful Completion Of A$7.5 Million Placement
QRxPharma Announces Successful Completion Of A$7.5 Million Placement Funding to provide working capital through the upcoming PDUFA date and commercialisation of ...
17.10.13 - PR Newswire
OTCM ADR Index Up 11.12% in Q3 2013, 12.75% Year-to-Date
OTCM ADR Index Up 11.12% in Q3 2013, 12.75% Year-​to-Date 67 companies joined Index in Q3, including AusTex Oil Limited, Dyesol Ltd., Invensys plc, Klabin S.A., QRxPharma ...
15.10.13 - PR Newswire
QRxPharma Extends MOXDUO® License With Aspen
QRxPharma Extends MOXDUO® License With Aspen Aspen exercises option and enters into license for South Africa PR Newswire
09.10.13 - PR Newswire
QRxPharma Reports Positive Meeting With The FDA On MOXDUO®
QRxPharma Reports Positive Meeting With The FDA On MOXDUO® FDA Provides Clear Objectives for Refiling NDA and Data Validation Documents PR Newswire
11.09.13 - PR Newswire
QRxPharma Announces MOXDUO® License With Aspen
QRxPharma Announces MOXDUO® License With Aspen Signs License Agreement for Australia, New Zealand and Oceania PR Newswire
06.09.13 - PR Newswire
FDA Schedules Review Meeting With QRxPharma Regarding MOXDUO® NDA
FDA Schedules Review Meeting With QRxPharma Regarding MOXDUO® NDA Meeting on 3 October to discuss remaining issues before refiling NDA PR Newswire
28.08.13 - PR Newswire
QRxPharma Receives Complete Response Letter From FDA Regarding MOXDUO® NDA
QRxPharma Receives Complete Response Letter From FDA Regarding MOXDUO® NDA PR Newswire
22.07.13 - PR Newswire
QRxPharma Announces Collaboration With Aesica
QRxPharma Announces Collaboration With Aesica Signs Agreement for Promotion of Stealth Beadlets® Abuse Deterrence Technology PR Newswire
26.06.13 - PR Newswire
QRxPharma Updates MOXDUO® NDA Review
QRxPharma Updates MOXDUO® NDA Review New Information to Delay Planned FDA Advisory Committee Meeting and PDUFA date PR Newswire
12.06.13 - PR Newswire
QRxPharma Granted US Patent On Hybrid Opioids
QRxPharma Granted US Patent On Hybrid Opioids Composition of Matter Patent Provides Coverage Until 2031 PR Newswire
17.05.13 - PR Newswire
FDA Sets 17 July 2013 For MOXDUO® Advisory Committee Meeting
FDA Sets 17 July 2013 For MOXDUO® Advisory Committee Meeting Committee to Review Respiratory Safety Data Comparing MOXDUO with Components PR Newswire
14.03.13 - PR Newswire
FDA Sets 26 August 2013 As New PDUFA Date For MOXDUO® NDA
FDA Sets 26 August 2013 As New PDUFA Date For MOXDUO® NDA Product Launch Anticipated Before End of Calendar Year Pending Successful NDA Review PR Newswire
16.01.13 - PR Newswire
QRxPharma and FDA Establish Path Forward for Resubmission Of MOXDUO® New Drug Application
QRxPharma and FDA Establish Path Forward for Resubmission Of MOXDUO® New Drug Application Successful NDA Review to Position Product for Approval and Subsequent ...

Newssuche

Videos

newspaper
09:15 Uhr -9,85%
Technical Trading: Sojabohnen Long bis Juli
Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »